| Model Name | Description |
| A2780 | Derived from human ovarian endometrioid adenocarcinoma; TP53 wild-type, cisplatin-sensitive; commonly used for chemotherapy and resistance studies. |
| ES-2 | Clear cell ovarian carcinoma model; TP53 mutant, PTEN-null; known for aggressive growth and used in studies of chemoresistance. |
| OV90 | High-grade serous ovarian carcinoma; TP53 mutant, BRCA1 wild-type; used in platinum-based and PARP inhibitor testing. |
| TOV112D | Endometrioid ovarian carcinoma; PTEN mutant, TP53 wild-type; used to evaluate PI3K/AKT/mTOR inhibitors and hormonal therapy response. |
| PA-1 | Ovarian teratocarcinoma with wild-type TP53; used for studying differentiation, tumor heterogeneity, and chemoresistance. |
| CAOV3 | High-grade serous ovarian carcinoma; TP53 mutant, BRCA1 wild-type; moderately responsive to platinum and taxane therapies, used for drug development. |